Recent Updates
Recently added Catalysts
XENE

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

Key Takeaway: BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on

Full Press Release Details

BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.
Conference Call/Webcast Information:
Date: Tuesday, November 8, 2022
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Listen-Only Audio Webcast: https://edge.media-server.com/mmc/p/s4tct434
Live Call Participant: Registration Link
To participate in the live call, please register using the following link (also noted above) to receive dial-in details and a unique PIN code: Register and receive dial-in details. The audio webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Xenon Pharmaceuticals Inc.
Last updated: Nov 1, 2022